Four IP takeaways from Novartis’ $9.7 billion acquisition of The Medicines Company

Over the weekend, Novartis struck one of the largest deals in the biopharma sectors this year, agreeing to pay $9.7 billion for cardiovascular specialist The Medicines Company


Get unlimited access to all IAM content